I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596704435 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 31, 2007 Signature:

(Lori Sims)

Patent Docket No. 282172002900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of:

Thomas W. DUBENSKY, Jr. et al.

Serial No.:

10/773,792

Filing Date:

February 6, 2004

For: LISTERIA ATTENUATED FOR ENTRY

INTO NON-PHAGOCYTIC CELLS, VACCINES COMPRISING THE LISTERIA, AND METHODS OF USE

THEREOF

Examiner:

J. Graser

Group Art Unit:

1645

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. A copy of the non-patent literature is submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

With the application; accordingly, no fee or separate requirements are required.
Before the mailing of a first Office Action after the filing of a Request for Continued
Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
(e)(1) has been provided.

08/06/2007 TLUU11 00000011 031952

10773792

02 FC:1806

180.00 DA

	Withi	n three months of the application filing date or before mailing of a first Office Action				
	on the	e merits; accordingly, no fee or separate requirements are required. However, if				
	applic	cable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.				
\boxtimes	After	receipt of a first Office Action on the merits but before mailing of a final Office Action				
	or Notice of Allowance.					
		A fee is required. A check in the amount of is enclosed.				
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to				
		this submission in duplicate.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is				
		believed to be due.				
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the				
	issue	fee.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the				
		amount of is enclosed.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal				
		form (PTO/SB/17) is attached to this submission in duplicate.				

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other

fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing <u>282172002900</u>.

Dated: July 31, 2007

Respectfully submitted,

Alicia J. Hager

Registration No.: 44,140

MORRISON & FOERSTER LLP 755 Page Mill Road Palo Alto, California 94304-1018 (650) 813-4296



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date February 6, 2004

First Named Inventor Thomas W. DUBENSKY, Jr.

Art Unit 1645

Examiner Name J. Graser

10/773,792

Complete if Known

(Use as many sheets as necessary)

 Sheet
 1
 of
 6
 Attorney Docket Number
 282172002900

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	
	1.	US-2001/0023072-A1	09-20-2001	Crawford et al.		
	2.	US-2002/0039588-A1	04-04-2002	Collier et al.		
	3.	US-2002/0141977-A1	10-03-2002	Collins et al.		
	4.	US-2002/0155108-A1	10-24-2002	Barbera-Guillem		
	5.	US-2002/0192193-A1	12-19-2002	Chokri et al.		
	6.	US-2003/0092177-A1	05-15-2003	Belardelli et al.		
	7.	US-2003/0119187-A1	06-26-2003	De Santis		
	8.	US-2003/0190682-A1	10-09-2003	Law et al.		
	9.	US-2004/0022761-A1	02-05-2004	Banchereau et al.		
	10.	US-2004/0037807-A1	02-26-2004	Goldman		
	11.	US-2004/0038398-A1	02-26-2004	Crawford et al.		
	12.	US-2005/0175630-A1	08-11-2005	Raz et al.		
	13.	US-2007/0031457-A1	02-08-2007	Dubensky, Jr. et al.		
	14.	6,403,080-B1	06-11-2002	Segal		
	15.	6,440,735-B1	08-27-2002	Gaeta		
	16.	6,497,876-B1	12-24-2002	Maraskovsky et al.		

Application Number

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳°	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
·	17.	Alonso, J.C. et al. (1991). "Characterization of recF Suppressors in Bacillus subtilis," Biochimie 73:277-280.					
	18.	Arikan, E. et al. (1986). "Sequences of the E. coli uvrB Gene and Protein," Nucleic Acids Research 14(6):2637-2650.					
	19.	Armstrong, A.C. et al. (2002). "Cellular Vaccine Therapy for Cancer," <i>Expert. Rev. Vaccines</i> 1(3):303-316.					
	20.	Asano, K. et al. (May 8, 1998). "Structural Basis for Binding of the Plasmid Collb-P9 Antisense Inc RNA to Its Target RNA with the 5'-rUUGGCG-3' Motif in the Loop Sequence," <i>J. Biol. Chem.</i> 273(19):11826-11838.					
	21.	Atalla, A. et al. (August 2003). "The pst Operon of Bacillus subtilis Is Specifically Induced by Alkali Stress," J. Bacteriol. 185(16):5019-5022.					

Examiner	Date
Signature	Considered
440,7000	

Complete if Known Substitute for form 1449/PTO 10/773,792 Application Number Filing Date February 6, 2004 **INFORMATION DISCLOSURE** Thomas W. DUBENSKY, Jr. First Named Inventor STATEMENT BY APPLICANT Art Unit 1645 (Use as many sheets as necessary) Examiner Name J. Graser of Sheet 2 6 Attorney Docket Number 282172002900

22.	Bahjat, K.S. et al. (November 2006). "Cytosolic Entry Controls CD8*-T-Cell Potency During Bacterial Infection," <i>Infection and Immunity</i> 74(11):6387-6397.	
23.	Baillie, L.W.J. et al. (June 1, 1998). "A Heat-Inducible <i>Bacillus subtilis</i> Bacteriophage Φ105 Expression System for the Production of the Protective Antigen of <i>Bacillus anthracis</i> ," <i>FEMS Microbiol. Lett.</i> 163(1):43-47.	
24.	Banchereau, J. et al. (March 19, 1998). "Dendritic Cells and the Control of Immunity," <i>Nature</i> 392(6673):245-252.	
25.	Banchereau, J. et al. (September 1, 2001). "Immune and Clinical Responses in Patients with Metastatic Melanoma to CD34 ⁺ Progenitor-Derived Dendritic Cell Vaccine," <i>Cancer Res.</i> 61:6451-6458.	
26.	Belitsky, B.R. et al. (July 2002). "GabR, A Member of a Novel Protein Family, Regulates the Utilization of γ-Aminobutyrate in <i>Bacillus subtilis</i> ," <i>Mol. Microbiol.</i> 45(2):569-583.	
27.	Bierne, H. et al. (November 1997). "uvrD Mutations Enhance Tandem Repeat Deletion in the Escherichia coli Chromosome via SOS Induction of the RecF Recombination Pathway," Mol. Microbiol. 26(3):557-567.	
28.	Brockstedt, D.G. et al. (September 21, 2004). "Listeria-based Cancer Vaccines That Segregate Immunogenicity From Toxicity," Supporting Information, Table and Figures cited in Proc. Natl. Acad. Sci. USA Data Supplement located at http://www.pnas.org/cgi/content/full/0406035101/DC1 , last visited on July 22, 2007, 9 pages.	
29.	Campoy, S. et al. (November 2002). "A New Regulatory DNA Motif of the Gamma Subclass Proteobacteria: Identification of the LexA Protein Binding Site of the Plant Pathogen Xylella fastidiosa," Microbiology 148:3583-3597.	
30.	Carrasco, B. et al. (2002). "Effect of the <i>recU</i> Suppressors <i>sms</i> and <i>subA</i> on DNA Repair and Homologous Recombination in <i>Bacillus subtilis</i> ," <i>Mol. Genet. Genomics</i> 266:899-906.	
31.	Chan, A.Y. et al. (October 10, 2003). "Interaction of a Putative Transcriptional Regulatory Protein and the Thermo-Inducible cts-52 Mutant Repressor in the Bacillus subtilis Phage φ 105 Genome," J. Mol. Biol. 333(1):21-31.	
32.	Chang, D.H. et al. (June 2003). "Dendritic Cells and Immunotherapy for Cancer," <i>Int. J. Hematol.</i> 77(5):439-443.	
33.	Clark, A.J. (1991). "rec Genes and Homologous Recombination Proteins in Escherichia coli," Biochemie 73:523-532.	
34.	Coote, J.G. et al. (January 1996). "A Rapid, Colourimetric Assay for Cytotoxin Activity in Campylobacter jejuni," FEMS Immunol. Med. Microbiol. 13(1):65-70.	
35.	Courcelle, J. et al. (July 17, 2001). "Participation of Recombination Proteins in Rescue of Arrested Replication Forks in UV-Irradiated <i>Escherichia coli</i> Need Not Involve Recombination," <i>Proc. Natl. Acad. Sci. USA</i> 98(15):8196-8202.	
36.	Crowley, D.J. et al. (May 10, 2001). "The SOS-Dependent Upregulation of <i>uvrD</i> is not Required for Efficient Nucleotide Excision Repair of Ultraviolet Light Induced DNA Photoproducts in <i>Escherichia coli</i> ," <i>Mutat. Res.</i> 485(4):319-329.	
37.	Davis, E.O. et al. (June 2002). "Definition of the Mycobacterial SOS Box and Use To Identify LexA-Regulated Genes in <i>Mycobacterium tuberculosis</i> ," <i>J. Bacteriol.</i> 184(12):3287-3295.	
38.	Deuerling, E. et al. (July 1995). "The <i>ftsH</i> Gene of <i>Bacillus subtilis</i> Is Transiently Induced after Osmotic and Temperature Upshift," <i>J. Bacteriol.</i> 177(14):4105-4112.	
39.	Dhodapkar, M.V. et al. (May 2000). "Active Immunization of Humans with Dendritic Cells," J. Clin. Immunol. 20(3):167-174.	

Examiner	Date	
Signature	Considered	

9.11	ostitute for form 1449/PTO			Complete if Known		
Sui	ostitute for form 1449/FTO			Application Number	10/773,792	
11	NFORMATION	l Di	SCLOSURE	Filing Date	February 6, 2004	
	TATEMENT E			First Named Inventor	Thomas W. DUBENSKY, Jr.	
Ŭ		<i>.</i>	W 1 2107 WY	Art Unit	1645	
(Use as many sheets as necess ary)				Examiner Name	J. Graser	
Sheet	3	of	6	Attorney Docket Number	282172002900	

40.	Dullaghan, E.M. et al. (November 2002). "The Role of Multiple SOS Boxes Upstream of the <i>Mycobacterium tuberculosis lexA</i> Gene - Identification of a Novel DNA-Damage-Inducible Gene," <i>Microbiology</i> 148(11):3609-3615.	
41.	Esche, C. et al. (February 1999). "The Use of Dendritic Cells for Cancer Vaccination," <i>Curr. Opin. Mol. Ther.</i> 1(1):72-81.	
42.	Fisher, S.H. (April 1999). "Regulation of Nitrogen Metabolism in <i>Bacillus subtilis</i> : vive la différence!" <i>Mol. Microbiol.</i> 32(2):223-232.	
43.	Franklin, W.A. et al. (June 1984). "Removal of UV Light-Induced Pyrimidine-Pyrimidone(6-4) Products from Escherichia coli DNA Requires the uvrA, uvrB, and urvC Gene Products," Proc. Natl. Acad. Sci. USA 81(12):3821-3824.	
44.	Fuangthong, M. et al. (June 2002). "Regulation of the <i>Bacillus subtilis fur</i> and <i>perR</i> Genes by PerR: Not All Members of the PerR Regulon Are Peroxide Inducible," <i>J. Bacteriol.</i> 184(12):3276-3286.	
45.	GenBank Accession No. AJ271621, created November 14, 2006, located at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=27527038 , last visited on June 30, 2007, four pages.	
46.	GenBank Accession No. AJ409321, created April 15, 2005, located at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?40643279:EMBL:10447457 , last visited on July 22, 2007, two pages.	
47.	Genbank Accession No. NC_007530, created April 3, 2006, located at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=50196905 , last visited on May 16, 2007, 163 pages.	
48.	GenBank Accession No. V00328, created April 18, 2005, located at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=42672 , last visited on May 16, 2007, three pages.	
49.	GenBank Accession No. X81135, created November 30, 2006, located at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?563492:EMBL:10735862 , last visited on July 22, 2007, three pages.	
50.	Griffiths, A.J.F. et al. (1999). Modern Genetic Analysis Integrating Genes and Genomes, Second Edition, W.H. Freeman and Company, New York, NY, pg. 315.	
51.	Haddad, E.E. et al. (October-December 1994). "Adaptation of the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl Tetrazolium Bromide) Assay for the Determination of Virus-Neutralizing Antibodies Using the Virus-Neutralization Assay," <i>Avian Dis.</i> 38(4):755-761.	
52.	Hall, J.D. et al. (March 1975). "Temperature-Sensitive recA Mutant of Escherichia coli K-12: Deoxyribonucleic Acid Metabolism After Ultraviolet Irradiation," J. Bacteriol. 121(3):892-900.	
53.	Hanna, M.N. et al. (October 2001). "uvrA Is an Acid-Inducible Gene Involved in the Adaptive Response to Low pH in Streptococcus mutans," J. Bacteriol. 183(20):5964-5973.	
54.	Hecker, M. et al. (February 1996). "Heat-Shock and General Stress Response in <i>Bacillus subtilis</i> ," <i>Mol. Microbiol.</i> 19(3):417-428.	
55.	Hering, D. et al. (March 2004). "Validation of the Anthrax Lethal Toxin Neutralization Assay," Biologicals 32(1):17-27.	
56.	Humrich, J. et al. (2003). "Viral Vectors for Dendritic Cell-Based Immunotherapy," Chapter 11 <i>In</i> Dendritic Cells and Virus Infection, Steinkasserer, A. ed., Springer-Verlag: Germany, 276:241-259.	
57.	Husain, I. et al. (April 15, 1986). "Sequences of Escherichia coli uvrA Gene and Protein Reveal Two Potential ATP Binding Sites," The Journal of Biological Chemistry 261(11):4895-4901.	

Examiner	Date
Signature	Considered
1407000	Considered

8	ostitute for form 1449/PTO			Complete if Known		
Sui	Stitute for form 1449/FTO			Application Number	10/773,792	
l IN	NFORMATION	1 DI	SCLOSURE	Filing Date	February 6, 2004	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Thomas W. DUBENSKY, Jr.	
				Art Unit	1645	
	(Use as many she	eets as	necess ary)	Examiner Name	J. Graser	
Sheet	4	of	6	Attorney Docket Number	282172002900	

58.	Ivánovics, G. (1962). "The Pathogenicity of <i>Bacillus anthracis</i> Lysogenic with Mutants of Phage W," J. Gen. Microbiol. 28:87-101.	
59.	Johansson, J. et al. (June 2003). "RNA-Mediated Control of Virulence Gene Expression in Bacterial Pathogens," <i>Trends Microbiol.</i> 11(6):280-285.	
60.	Johnston, J.L. et al. (March 1997). "The <i>RecA</i> Gene from <i>Clostridium perfringens</i> is Induced by Methyl Methanesulphonate and Contains an Upstream Cheo Box," <i>Microbiology</i> 143(3):885-890.	
61.	Kaan, T. et al. (November 2002). "Genome-Wide Transcriptional Profiling of the <i>Bacillus subtilis</i> Cold-Shock Response," <i>Microbiol.</i> 148(11):3441-3455.	
62.	Kawai, Y. et al. (February 2003). "Identification of a Protein, YneA, Responsible for Cell Division Suppression During the SOS Response in <i>Bacillus subtilis</i> ," <i>Mol. Microbiol.</i> 47(4):1113-1122.	
63.	Kuzminov, A. (December 1999). "Recombinational Repair of DNA Damage in <i>Escherichia coli</i> and Bacteriophage λ," <i>Microbiol. Mol. Biol. Rev.</i> 63(4):751-813.	
64.	Lecuit, M. (December 1997). "Internalin of <i>Listeria monocytogenes</i> with an Intact Leucine-Rich Repeat Region Is Sufficient To Promote Internalization," <i>Infection and Immunity</i> 65(12):5309-5319.	
65.	Lin, J-J. et al. (December 5, 1990). "Reconstitution of Nucleotide Excision Nuclease with UvrA and UvrB Proteins from <i>Escherichia coli</i> and UvrC Protein from <i>Bacillus subtilis</i> ," <i>J. Biol. Chem.</i> 265(34):21337-21341.	
66.	Lin, L. et al. (May 1, 1994). "Photochemical Inactivation of Pathogenic Bacteria in Human Platelet Concentrates," <i>Blood</i> 83(9):2698-2706.	
67.	Lingnau, A. et al. (October 1995). "Expression of the Listeria monocytogenes EGD inlA and inlB Genes, Whose Products Mediate Bacterial Entry into Tissue Culture Cell Lines, by PrfA-Dependent and Independent Mechanisms," Infection and Immunity 63(10):3896-3903.	
68.	Lipman, D.J. (September 15, 1997). "Making (Anti)Sense of Non-Coding Sequence Conservation," Nucleic Acids Res. 25(18):3580-3583.	
69.	Lovett, C.M. et al. (November 1993). "Purification of an SOS Repressor from <i>Bacillus subtilis</i> ," <i>J. Bacteriol.</i> 175(21):6842-6849.	
70.	Lovett, C.M. Jr. et al. (August 1994). "Analysis of the SOS Inducing Signal in <i>Bacillus subtilis</i> using <i>Escherichia coli</i> LexA as a Probe," <i>J. Bacteriol.</i> 176(16):4914-4923.	
71.	Lu, W. et al. (January 2003). "Therapeutic Dendritic-Cell Vaccine for Simian AIDS," <i>Nature Medicine</i> 9(1):27-32.	
72.	Mao, J-R. et al. (August 25, 1995). "Gene Regulation by Antisense DNA Produced in Vivo," J. Biol. Chem. 270(34):19684-19687.	
73.	McGuire, A.M. et al. (May 2000). "Conservation of DNA Regulatory Motifs and Discovery of New Motifs in Microbial Genomes," <i>Genome Res.</i> 10(5):744-757.	
74.	Meletiadis, J. et al. (August 2000). "Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In Vitro Susceptibility Testing of Filamentous Fungi and Development of a New Simplified Method," J. Clin. Microbiol. 38(8):2949-2954.	
75.	Mengaud, J. et al. (March 22, 1996). "E-Cadherin Is the Receptor for Internalin, a Surface Protein Required for Entry of L. monocytogenes into Epithelial Cells," Cell 84:923-932.	
76.	Miller, M.C. et al. (December 27, 1996). "The <i>Bacillus subtilis dinR</i> Gene Codes for the Analogue of <i>Escherichia coli</i> LexA," <i>J. Biol. Chem.</i> 271(52):33502-33508.	
77.	Mongkolsuk, S. et al. (July 2002). "Regulation of Inducible Peroxide Stress Responses," <i>Mol. Microbiol.</i> 45(1):9-15.	•

Examiner	Date	
Signature	Considered	

Substitute for form 1449/PTO		Complete if Known			
Substitute for form 1449/PTO				Application Number	10/773,792
IN	NFORMATION	I DI	SCLOSURE	Filing Date	February 6, 2004
	STATEMENT BY APPLICANT			First Named Inventor	Thomas W. DUBENSKY, Jr.
(Use as many sheets as necessary)			11 1 21071111	Art Unit	1645
			necess ary)	Examiner Name	J. Graser
Sheet	5	of	6	Attorney Docket Number	282172002900

78.	Mota, L.J. et al. (July 2001). "Control of the Arabinose Regulon in <i>Bacillus subtilis</i> by AraR In Vivo: Crucial Roles of Operators, Cooperativity, and DNA Looping," <i>J. Bacteriol.</i> 183(4):4190-4201.	
79.	Movahedzadeh, F. et al. (March 1997). "Characterization of <i>Mycobacterium tuberculosis</i> LexA: Recognition of a Cheo (<i>Bacillus</i> -type SOS) Box," <i>Microbiology</i> 143(3):929-936.	
80.	Mu, D. et al. (1997). "DNA Excision Repair Assays" In Progress in Nucleic Acid Research and Molecular Biology, Cohn, W.E. et al. eds., Academic Press, Inc.: San Diego, CA, 56:63-81.	
81.	Munakata, N. et al. (November 1991). "Inactivation Action Spectra of <i>Bacillus subtilis</i> Spores in Extended Ultraviolet Wavelengths (50-300 nm) Obtained with Synchrotron Radiation," <i>Photochem. Photobiol.</i> 54(5):761-768.	
82.	Nickel, M. et al. (August 2004). "Cold Induction of the <i>Bacillus subtilis bkd</i> Operon is Mediated by Increased mRNA Stability," <i>Mol. Genet. Genomics</i> 272(1):98-107.	
83.	Noone, D. et al. (March 2000). "Expression of ykdA, Encoding a Bacillus subtilis Homologue of HtrA, Is Heat Shock Inducible and Negatively Autoregulated," J. Bacteriol. 182(6):1592-1599.	
84.	Office Action mailed January 26, 2007, for U.S. Application No. 10/773,618, filed February 6, 2004, 22 pages.	
85.	Office Action mailed March 8, 2007, for U.S. Application No. 10/883,599, filed June 30, 2004, 6 pages.	
86.	Palucka, A.K. et al. (September/October 2003). "Single Injection of CD34+ Progenitor-Derived Dendritic Cell Vaccine Can Lead to Induction of T-Cell Immunity in Patients With Stage IV Melanoma," J. Immunother. 26(5):432-439.	
87.	Ramaswamy, M. et al. (January 7, 1994). "Sequence-Specific Interactions of UvrABC Endonuclease with Psoralen Interstrand Cross-Links," <i>J. Biol. Chem.</i> 269(1):485-492.	
88.	Repoila, F. et al. (November 2003). "Temperature Sensing by the dsrA Promoter," J. Bacteriol. 185(22):6609-6614.	
89.	Sakamoto, T. et al. (February 2002). "Regulation of the Desaturation of Fatty Acids and its Role in Tolerance to Cold and Salt Stress," <i>Curr. Opin. Microbiol.</i> 5(1):206-210.	
90.	Sancar, A. (1996). "DNA Excision Repair," Annu. Rev. Biochem. 65:43-81.	
91.	Santini, S.M. et al. (2003). "Advances in the Use of Dendritic Cells and New Adjuvants for the Development of Therapeutic Vaccines," <i>Stem Cells</i> 21(4):495-505.	
92.	Schofield, D.A. et al. (June 2003). "Development of a Thermally Regulated Broad-Spectrum Promoter System for Use in Pathogenic Gram-Positive Species," <i>Appl. Environ Microbiol.</i> 69(6):3385-3392.	
93.	Schönert, S. et al. (April 1999). "Properties of Maltose-Inducible α-Glucosidase MalL (Sucrase-Isomaltase-Maltase) in <i>Bacillus subtilis</i> : Evidence for its Contribution to Maltodextrin Utilization," <i>Res. Microbiol.</i> 150(3):167-177.	
94.	Schuler, G. et al. (April 2003). "The Use of Dendritic Cells in Cancer Immunotherapy," Curr. Opin. Immunol. 15(2):138-147.	
95.	Stülke, J. et al. (July 1997). "Induction of the <i>Bacillus subtilis ptsGHI</i> Operon by Glucose is Controlled by a Novel Antiterminator, GlcT," <i>Mol. Microbiol.</i> 25(1):65-78.	
96.	Wagner, E.G.H. et al. (1994). "Antisense RNA Control in Bacteria, Phages, and Plasmids," <i>Ann. Rev. Microbiol.</i> 48:713-742.	
97.	Walsh, S.R. et al. (April 2003). "Dendritic Cells and the Promise of Therapeutic Vaccines for Human Immunodeficiency Virus (HIV)-1," <i>Curr. HIV Res.</i> 1:205-216.	
98.	Wang, B. et al. (March 28, 2003). "Assessment of the Utilization of the Antisense RNA Strategy to Identify Essential Genes in Heterologous Bacteria," FEMS Microbiol. Lett. 220(2):171-176.	

Examiner	Date	
Signature	Considered	

Substitute for form 1440/DTO				Complete if Known		
Substitute for form 1449/PTO				Application Number	10/773,792	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	February 6, 2004	
	STATEMENT BY APPLICANT			First Named Inventor	Thomas W. DUBENSKY, Jr.	
OTATEMENT BY ALL EIGAN			-11 / 210/1111	Art Unit	1645	
(Use as many sheets as necess ary)				Examiner Name	J. Graser	
Sheet	6	of	6	Attorney Docket Number	282172002900	

	J. Bacteriol. 179(5):1698-1703.	
100.	Wong, K.K.Y. et al. (2004). "Evidence Implicating the 5' Untranslated Region of <i>Listeria monocytogenes actA</i> in the Regulation of Bacterial Actin-Based Motility," <i>Cellular Microbiology</i> 6(2):155-166.	
101.	Yansura, D.G. et al. (January 1984). "Use of the Escherichia coli lac Repressor and Operator to Control Gene Expression in Bacillus subtilis," Proc. Natl. Acad. Sci USA 81(2):439-443.	
102.	Yasbin, R.E. et al. (May 1992). "Inducible DNA Repair and Differentiation in <i>Bacillus subtilis</i> : Interactions Between Global Regulons," <i>Mol. Microbiol.</i> 6(10):1263-1270.	
103.	Zhang, X. et al. (November 6, 2002). "Advances in Dendritic Cell-Based Vaccine of Cancer," <i>Cancer Biother. Radiopharm.</i> 17(6):601-619.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.